This promotional document has been developed, reviewed and certified by Boehringer Ingelheim. Prescribing information and adverse event reporting information is on the next page. For UK and Irish healthcare professionals only.

The practicalities of addressing diabetes distress

More common

high management

in women³,

people with complications³ or a

burden⁴



Diabetes distress – what is it?

"The negative emotional or affective experience resulting from the challenge of living with the demands of diabetes, regardless of the type of diabetes"


How prevalent is it?

People with type 1 diabetes²

People with type 2 diabetes²



Diabetes UK 7 As model for managing distress²



How can I identify diabetes distress?²

Be aware that people with diabetes may experience diabetes distress

- Consider the signs of diabetes distress:²
 - Unstable glucose -
 - Clinic non-attendance or passive or 2 aggressive consultations
 - Reduced engagement in diabetes self-care
 - Ineffective coping strategies
 - Other life events or impaired relationships

Ask about diabetes distress

- Diabetes distress is often overlooked and not investigated
- Recommended questions to ask:
- 1. What is the most difficult part of living with diabetes for you?
- 2. What are your greatest concerns about your diabetes?
- 3. How is your diabetes getting in the way of other things in your life right now?

Assess diabetes distress using one of the following questionnaires:

- Diabetes Distress Scale (DDS)⁵
- Type 1 Diabetes Distress Scale (T1-DDS)⁶
- Problem Areas in Diabetes (PAID) Type 1 & 27
- Short forms or screeners
- DDS-2 and DDS-48
- PAID-59



How can I support a person who experiences diabetes distress?²

Advise about diabetes distress

- Explain what diabetes distress is¹
- Diabetes distress matters due to its association with higher glucose levels, poorer quality of life, ability to follow dietary advice, take regular exercise and medications²
- Acknowledge the significant daily efforts required to manage diabetes²

Assist with developing an action plan

Language matters in diabetes¹¹

respectful and empathetic

Remove bias, blame, irreverence, authority

Show we care by being curious, accurate,

and stigma

Assign to another HCP Interventions to help support people with diabetes

- experiencing diabetes distress:10 Psychological (CBT and motivational interviewing)
- Educational (DSME)
- Technology (CBGM, web applications/e-health technology and insulin titration tools)
- Peer support
- Psychoeducational interventions

Arrange follow up care and additional support

• Extended consultations or more frequent follow-up visits²





Remember

- TRAJENTA (linagliptin): Has a simple dosing regimen of one 5 mg dose once daily, irrespective of renal or hepatic function, and age¹²
- TRAJENTA (linagliptin) is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as¹²:
 - Monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
 - Combination therapy in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

Please review the Summary of Product Characteristics for TRAJENTA (linagliptin) for the full information on dosing, adverse events, contraindications and monitoring before prescribing¹²

CBGM: continuous blood glucose monitoring; CBT: cognitive behavioural therapy; DSME: diabetes self-management education; HCP: healthcare professional; T1D: type 1 diabetes; T2D: type 2 diabetes

1. Skinner TC et al. Diabet Med 2020;37:393-400; 2. Hendrieckx C et al. Diabetes and emotional health: a practical guide for healthcare professionals supporting adults with Type 1 and Type 2 diabetes. London: Diabetes UK, 2019, 2nd Edition (UK); 3. Perrin NE et al. Diabet Med 2017;34:1508–1520; 4. Baek RN et al. Ann Behav Med 2014;48:145–155; 5. Polonsky WH et al. Diabetes Care 2005;28:626–631; 6. Fisher et al. J Diabetes Complications 2015;29: 572-577; 7. Polonsky WH et al. Diabetes care 1995;18:754-760; 8. Fisher L et al. Ann Fam Med 2008;6:246-252; 9. McGuire BE et al. Diabetologia 2010;53:66-69; 10. Sturt J et al. Int Diab Nurs 2015;12:40-55; 11. NHS England. Language matters: Language and diabetes. 2023. Available at: https://www.england.nhs.uk/wp-content/uploads/2018/06/language-matterslanguage-and-diabetes-v2.pdf (accessed February 2024); 12. TRAJENTA (linagliptin) Summary of Product Characteristics. Available at: www.medicines.org.uk (GB), www.emcmedicines.com/en-GB/ northernireland/ (NI) and https://www.medicines.ie/medicines/trajenta-5-mg-film-coated-tablets-34014/spc (ROI) (accessed February 2024).

Prescribing Information (Great Britain) TRAJENTA® (Linagliptin)

Film-coated tablets containing 5 mg linagliptin. Indication: Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as: monotherapy when metformir is inappropriate due to intolerance, or contraindicated due to renal impairment; combination therapy in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control. Dose and Administration: 5 mg once daily. If added to metformin, the dose of metformin should be maintained and linagliptin administered concomitantly. When used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin, may be considered to reduce the risk of hypoglycaemia. Renal impairment: no dose adjustment required. Hepatic impairment: pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment but clinical experience in such patients is lacking. *Elderly:* no dose adjustment is necessary based on age. *Paediatric population:* the safety and efficacy of linagliptin in children and adolescents has not yet been established. No data are available. The tablets can be taken with or without a meal at any time of the day. If a dose is missed, it should be taken as soon as possible but a double dose should not be taken on the same day. Contraindications: Hypersensitivity to the active substance or to any of the excipients Warnings and Precautions: Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Hypoglycaemia: Caution is advised when linagliptin is used in combination with a sulphonylurea and/or insulin; a dose reduction of the sulphonylurea or insulin may be considered. Acute pancreatitis: Acute pancreatitis has been observed in patients taking linagliptin. Patients should be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, Trajenta should be discontinued. If acute pancreatitis is confirmed. Traienta should not be restarted. Caution should be exercised in patients with a history of pancreatitis. Bullous pemphigoid: Bullous pemphigoid has been observed in patients taking Linagliptin. If bullous pemphigoid is suspected, Trajenta should be discontinued. Interactions: Linagliptin is a weak competitive and a weak to moderate mechanism-based inhibitor of CYP isozyme CYP3A4, but does not inhibit other CYP isozymes. It is not an inducer of CYP isozymes. Linagliptin is a P-glycoprotein substrate and inhibits P-glycoprotein mediated transport of digoxin with low potency. Based on these results and in vivo interaction studies, linagliptin is considered unlikely to cause

Interactions with other P-glycoprotein substrates. *Effects of other medicinal products on linagliptin*: The risk for clinically meaningful interactions by other medicinal products on linagliptin is low. *Rifampicin:* Multiple co-administration of S mg linagliptin with rifampicin, a potent inductor of P-glycoprotein and CVP3A4, decreased linagliptin steady state AUC and Cmax. Thus, full efficacy of linagliptin in combination with strong P-glycoprotein inducers of P-glycoprotein and CVP3A4, such as carbamazepine, phenobarbital and phenytoin has not been studied. *Effects of linagliptin on other medicinal products:* In clinical studies linagliptin had no clinically relevant effect on the pharmacokinetics of metformin, glibenclamide, simvastatin, warfarin, digoxin or oral contraceptives (please refer to Summary of Product Characteristics for a full list of interactions and clinical data). **Fertility, pregnancy and lactation:** The use of linagliptin has not been studied in pregnant women. As a precautionary measure, avoid use during pregnancy. A risk to the breast-fed child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from linagliptin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. No studies on the effect on human fertility have been conducted for linagliptin. **Undesirable effects:** Adverse reactions reported in patients who received linagliptin 5 mg daily as monotherapy or as add-on therapies in clinical trials and from post-marketing experience. Frequencies are defined as very common (≥1/100, 0. Adverse reactions with lingliptin 5 mg daily as monotherapy: common: hypoglycaemia. Adverse reaction with lingliptin in combination with metformin plus sulphon/lurea: Very common: hypoglycaemia. Adverse reaction with lingliptin in combination with metformin plus sulphon/lurea: Very common: hypoglycaemia. Adverse reaction with lingliptin in combination with metformin plus sulphon/lurea: Very co

PC-GB-100923 V3 Date of preparation July 2023

Prescribing Information (Northern Ireland) TRAJENTA® (Linagliptin)

Film-coated tablets containing 5 mg linagliptin. Indication: Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as: monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment; combination therapy in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control. Dose and Administration: 5 mg once daily. If added to metformin, the dose of metformin should be maintained and linagliptin administered concomitantly. When used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin, may be considered to reduce the risk of hypoglycaemia. *Renal impairment:* no dose adjustment required. Hepatic impairment but clinical experience in such patients is lacking. *Elderly*: no dose adjustment is necessary based on age. *Paediatric population:* a clinical trial did not establish efficacy in paediatric patients with hepatic impairment but clinical experience in such patients with linagliptin is not recommende. Linagliptin has not been studied in paediatric patients under 10 years of age. The tablets can be taken with or without a meal at any time of the day. If a dose is missed, it should be taken as soon as possible but a double dose should not be taken on the same day. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. Warnings and Precautions: Linagliptin hosolud not be used in patients visit paper advor insulin; a dose reduction of the sulphonylurea or insulin. Patients should be discontinued. If acute pancreatitis has been observed in patients taking linagliptin. Patients should be discontinued. If acute pancreatitis is confirmed, Trajenta should not be restarted. *Acute pancreatitis:* Acute pancreatitis is confirmed, Trajenta should not be erestrated. Caution should be discontinued. If acute pancreatitis is confirmed, Trajenta should not b

unlikely to cause interactions with other P-glycoprotein substrates. *Effects of other medicinal products on linagliptin:* The risk for clinically meaningful interactions by other medicinal products on linagliptin is low. Rifampicin: Multiple co-administration of 5 mg linagliptin with rifampicin, a potent inductor of P-glycoprotein and CYP3A4, decreased linagliptin steady state AUC and Cmax. Thus, full efficacy of linagliptin in combination with strong P-glycoprotein inducers of P-glycoprotein and CYP3A4, decreased linagliptin steady state AUC and Cmax. Thus, full efficacy of linagliptin in combination with strong P-glycoprotein inducers of P-glycoprotein and CYP3A4, such as carbamazepine, phenobarbital and phenytoin has not been studied. *Effects of linagliptin on other medicinal products:* In clinical studies linagliptin had no clinically relevant effect on the pharmacokinetics of metformin, glibenclamide, simvastatin, warfarin, digoxin or oral contraceptives (please refer to Summary of Product Characteristics for a full list of interactions and clinical data). Fertility, pregnancy and lactation: The use of linagliptin has not been studied. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from linagliptin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. No studies on the effect on human fertility have been conducted for linagliptin. Undesirable effects: Adverse reactions reported in patients who received linagliptin 5 mg daily as monotherapy or as add-on therapies in clinical trials and from post-marketing experience. Frequencies are defined as very common ($\geq 1/10,000$). *Adverse reactions with lingliptin 5 mg daily as monotherapy*. Common: lapopalynapylitis, hypersensitivity; cuesh; rash; amylase increased. Rare: pancreatitis; angloedema; urticaria; bullous pemphigold. *Adverse reaction with lingliptin in combination with metformin plus sulphonylurea*: Very common: hypoglycaemia. Adverse reaction with li

PC-GB-104346 V4 Date of preparation May 2023

Prescribing Information (Ireland) TRAJENTA® (Linagliptin)

Film-coated tablets containing 5 mg linagliptin. Indication: Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as: monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment; combination therapy in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control. Dose and Administration: 5 mg once daily. If added to metformin, the dose of metformin should be maintained and linagliptin administered concontiantly. When used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin, may be considered to reduce the risk of hypoglycaemia. *Renal impairment*: no dose adjustment required. *Hepatic impairment*: pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment: but clinical experience in such patients is lacking. Elderly: no dose adjustment is necessary based on age. *Paediatric population*: a clinical trial did not establish efficacy in paediatric patients 10 to 17 years of age. Therefore, treatment of children and adolescents with linagliptin is not recommended. Linagliptin has not been studied in paediatric patients under 10 years of age. The tablets can be taken with or without a meal at any time of the day. If a dose is missed, it should be taken as soon as possible but a double dose should not be taken on the same day. **Contraindications**: Hypersensitivity to the active substance or to any of the excipients. Warnings and Precautions: Linagliptin is oute pancreatitis is subpected, Trajenta should be discontinued. If acute pancreatitis is confirmed, Trajenta should not be restarted. Caution should be discontinued. If acute pancreatitis is confirmed, Trajenta should not be restrated. Caution should be discontinued. If acute pancreatitis is confirmed, Trajenta should not be restrated. Teancrestitis is suspected, Trajenta sh

PC-IE-100681 V5 Date of preparation May 2023

For more information or to access the Summary of Product Characteristics please visit www.medicines.org.uk/emc (GB), www.emcmedicines.com (NI) or www.medicines.ie (IE).

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or

https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: PV_local_UK_Ireland@boehringer-ingelheim.com.



